| Identification | Back Directory | [Name]
TocilizuMab | [CAS]
375823-41-9 | [Synonyms]
R 1569
Actemra
Atlizumab
RoActemra
TocilizuMab
Actemra 200
Tocilizumab-Actemra
Tocilizumab,Atlizumab
anti-IL-6R Tocilizumab
Tocilizumab (anti-IL-6R) | [EINECS(EC#)]
248-451-4 | [Molecular Formula]
C14H12O3 | [MDL Number]
MFCD01633115 |
| Hazard Information | Back Directory | [Uses]
Tocilizumab (Anti-Human IL6R, Humanized Antibody) is an anti-human interleukin-6 receptor (IL-6R) neutralizing antibody, prevents binding of IL-6 to the IL-6R, thereby inhibiting both classic and trans-signaling. Tocilizumab (Anti-Human IL6R, Humanized Antibody) can be used for the treatment of rheumatoid arthritis[1]. Tocilizumab is remarkablely effective for the study of severe COVID-19 (coronavirus disease)[4]. | [Clinical Use]
Interleukin inhibitor:
Treatment of rheumatoid arthritis in combination with methotrexate | [in vivo]
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intravenous injection; 1.0 mg/100 μL; twice a week, three weeks) decreases the volume of each metastatic focus in tocilizumab-injected mouse brains[2].
Tocilizumab (Anti-Human IL6R, Humanized Antibody) (intraperitoneal injection;100 μg/mL, every 48 hours; 20days) suppresses OSCC progression and suppresses Tumor Angiogenesis[3]. | Animal Model: | A brain metastasis model of lung tumor cells by inoculating HARA-B cells in nude mice[2] | | Dosage: | 1.0 mg/100 μL | | Administration: | Intravenous injection; 1.0 mg/100 μL; twice a week, three weeks | | Result: | Led the volume of each metastatic focus significantly smaller. |
| Animal Model: | SCID mice with SAS cells[3] | | Dosage: | 100 μg/mL | | Administration: | Intraperitoneal injection;100 μg/mL; every 48 hours; 20days | | Result: | Suppressed the growth of advanced tumors. |
| [Drug interactions]
Potentially hazardous interactions with other drugs
Live vaccines: avoid concomitant administration | [IC 50]
IL-6 | [Metabolism]
Tocilizumab undergoes biphasic elimination from the circulation. The total clearance of tocilizumab is concentration-dependent and is the sum of the linear and non-linear clearance. The concentration-dependent non-linear clearance plays a major role at low tocilizumab concentrations. Once the non-linear clearance pathway is saturated, at higher tocilizumab concentrations, clearance is mainly determined by the linear clearance. | [storage]
Store at -80°C | [References]
[1] Garbers C, et al. Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem. 2011 Dec 16;286(50):42959-70. DOI:10.1074/jbc.M111.295758
[2] Mami Noda, et al. IL-6 Receptor Is a Possible Target against Growth of Metastasized Lung Tumor Cells in the Brain. Int J Mol Sci. 2013 Jan; 14(1): 515–526. DOI:10.3390/ijms14010515
[3] Shinriki S, et al. Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivogrowth of human oral squamous cell carcinoma. Clin Cancer Res. 2009 Sep 1;15(17):5426-34. DOI:10.1158/1078-0432.CCR-09-0287
[4] Chi Zhang, et al. Cytokine Release Syndrome in Severe COVID-19: Interleukin-6 Receptor Antagonist Tocilizumab May Be the Key to Reduce Mortality. Int J Antimicrob Agents. 2020 May;55(5):105954. DOI:10.1016/j.ijantimicag.2020.105954 |
|
|